🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 8 of 15

  1. Obexelimab

    Zenas BioPharma

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  2. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  3. Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  4. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  5. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  6. PIPE-307 Dose A

    Contineum Therapeutics

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  7. PRENUMBRA

    Clinuvel Europe Limited

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  8. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  9. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  10. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  11. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  12. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  13. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  14. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  15. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  16. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  17. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial

  18. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  19. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  20. Placebo

    Teva Pharma GmbH

    Primary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  21. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  22. Placebo RO7269162, RO7269162, RO7269162, RO7269162, FLORBETABEN (18F), FLUTEMETAMOL (18F)

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  23. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  24. Placebo of Dexamfetamine sulfate 20 mg modified-release capsule, Dexamfetamine sulfate 20 mg modified-release capsule, Attentin 5 mg, Tablette, Dexamfetamine sulfate 15 mg modified-release capsule, Dexamfetamine sulfate 10 mg modified-release capsule, Placebo of Attentin 5 mg 10 mg tablets, Placebo of Dexamfetamine sulfate 15 mg modified-release capsule, Attentin 10 mg Tablette, Placebo of Dexamfetamine sulfate 10 mg modified-release capsule

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  25. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  26. Placebo to MK-1167, MK-1167, MK-1167, MK-1167

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  27. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  28. PrimeC

    NeuroSense Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  29. Proleukin

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  30. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  31. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  32. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  33. RAP-219

    Rapport Therapeutics

    Focal Epilepsy

    phase 2 small molecule active

    1 trial

  34. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  35. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  36. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  37. ROT-TDS, Neupro 8 mg/24 h transdermal patch, Neupro 8 mg/24 h transdermal patch

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  38. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial

  39. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  40. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  41. Risperidone

    Indivior Pty Ltd

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  42. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  43. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  44. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  45. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  46. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  47. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  48. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.